Abstract
This letter refers to the recent demonstration that HIV-1 infected macrophages form specialized conduits that connect to B-cells (1). The conduit selectively transports the HIV-1 nef protein, providing nef with numerous means to interfere with cellular processes. Currently, no consideration of the connection between the conduit and the development of AIDS-related lymphoma (ARL) has been offered. ARL is one of the primary causes of death in the HIV-infected population and is related to B-cell proliferation and activation. In this letter we discuss several studies that link HIVinfected macrophages and specific forms of the nef protein to the development of ARL. The conduits discovered by Xu et al. [1] may lead to a better understanding of how HIV infection results in lymphomagenesis.
Keywords: HIV-1, AIDS-related lymphoma, macrophages, HIV-1 nef protein, Pathogenesis, B-cells, lymphomagenesis, virus-specific immunoglobin responses (IgG2 and IgA), CD40-dependent activation, metastatic, cytokines, cytidine deaminase-associated DNA, modification, Epstein Barr virus (EBV), tumorogenesis, immortalization, proliferation, tumor biopsies, Monocyte-derived, inflammation, malignancy, IFN, IL-4, IL-13, IL-10, viral load, MHC class II receptors, trans-golgi network (TGN), lysosomal degradation, myristoylation domain, cytosolic, dementia, mutation rate, RNAs
Current HIV Research
Title: HIV-1 Nef Protein Visits B-Cells via Macrophage Nanotubes: A Mechanism for AIDS-Related Lymphoma Pathogenesis?
Volume: 8 Issue: 8
Author(s): Susanna L. Lamers, Gary B. Fogel, Leanne C. Huysentruyt and Michael S. McGrath
Affiliation:
Keywords: HIV-1, AIDS-related lymphoma, macrophages, HIV-1 nef protein, Pathogenesis, B-cells, lymphomagenesis, virus-specific immunoglobin responses (IgG2 and IgA), CD40-dependent activation, metastatic, cytokines, cytidine deaminase-associated DNA, modification, Epstein Barr virus (EBV), tumorogenesis, immortalization, proliferation, tumor biopsies, Monocyte-derived, inflammation, malignancy, IFN, IL-4, IL-13, IL-10, viral load, MHC class II receptors, trans-golgi network (TGN), lysosomal degradation, myristoylation domain, cytosolic, dementia, mutation rate, RNAs
Abstract: This letter refers to the recent demonstration that HIV-1 infected macrophages form specialized conduits that connect to B-cells (1). The conduit selectively transports the HIV-1 nef protein, providing nef with numerous means to interfere with cellular processes. Currently, no consideration of the connection between the conduit and the development of AIDS-related lymphoma (ARL) has been offered. ARL is one of the primary causes of death in the HIV-infected population and is related to B-cell proliferation and activation. In this letter we discuss several studies that link HIVinfected macrophages and specific forms of the nef protein to the development of ARL. The conduits discovered by Xu et al. [1] may lead to a better understanding of how HIV infection results in lymphomagenesis.
Export Options
About this article
Cite this article as:
L. Lamers Susanna, B. Fogel Gary, C. Huysentruyt Leanne and S. McGrath Michael, HIV-1 Nef Protein Visits B-Cells via Macrophage Nanotubes: A Mechanism for AIDS-Related Lymphoma Pathogenesis?, Current HIV Research 2010; 8 (8) . https://dx.doi.org/10.2174/157016210794088209
DOI https://dx.doi.org/10.2174/157016210794088209 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alcoholic Liver Disease and Hepatitis C Chronic Infection
Reviews on Recent Clinical Trials The Small Bowel: An Imaging Guide
Current Medical Imaging Quantization of Angiogenesis and Image Analysis
Current Angiogenesis (Discontinued) Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?
Recent Patents on Anti-Cancer Drug Discovery The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Parenteral Drug Delivery: A Review
Recent Patents on Drug Delivery & Formulation Similar Mechanisms Regulated by γ-Secretase are Involved in Both Directions of the Bi-Directional Notch-Delta Signaling Pathway as well as Play a Potential Role in Signaling Events Involving Type 1 Transmembrane Proteins
Current Stem Cell Research & Therapy Application of Small Molecules/Macromolecules in Ocular Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Leptin, Estrogens and Cancer
Mini-Reviews in Medicinal Chemistry The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology The Use of Nimesulide and Its Analogues in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Capturing and Amplifying Impurities from Recombinant Therapeutic Proteins Via Combinatorial Peptide Libraries: A Proteomic Approach
Current Pharmaceutical Biotechnology